About 1 in 8 U.S. adults have taken Ozempic or similar medications used to treat Type 2 diabetes and obesity. While these ...

Ozempic breasts refer to changes in breast size or shape due to weight loss from GLP-1 drugs. Here’s how and why this side ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

Researchers at the University of Copenhagen have developed a new weight-loss drug that may surpass the effectiveness of ...

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Looking ahead, we are excited to start our Phase 1 trial of RT-114 containing a GLP-1/GLP-2 dual agonist for the treatment ... intended to replace subcutaneous injection or intravenous infusion of ...

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...

Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

Lixisenatide: A type of glucagon-like peptide-1 (GLP-1) receptor agonist to help lower blood sugar in people with type 2 ...

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

The company’s lead product is a long-acting GLP-1 drug known as MET-097i. In a Phase 1 trial, five weekly injections of the ...